Get the Stockscreener App
2.85
3.39%
-0.10
After Hours:
2.85
Akebia Therapeutics Inc stock is traded at $2.85, with a volume of 2.57M.
It is down -3.39% in the last 24 hours and down -8.95% over the past month.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
See More
Previous Close:
$2.95
Open:
$2.99
24h Volume:
2.57M
Relative Volume:
0.73
Market Cap:
$755.66M
Revenue:
$194.75M
Net Income/Loss:
$-51.26M
P/E Ratio:
-10.18
EPS:
-0.28
Net Cash Flow:
$-23.38M
1W Performance:
+6.34%
1M Performance:
-8.95%
6M Performance:
+69.64%
1Y Performance:
+115.91%
1-Day Range:
$2.83
$3.02
1-Week Range:
$2.66
$3.02
52-Week Range:
$1.255
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Name
Akebia Therapeutics Inc
Sector
Phone
617-871-2098
Address
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
2.85 | 782.18M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
143.49 | 63.27B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.31 | 45.67B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.04 | 39.27B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.21 | 23.02B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
448.93 | 20.66B | 3.08B | 1.24B | 1.07B | 25.61 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Resumed | H.C. Wainwright | Buy |
| Apr-28-25 | Initiated | Leerink Partners | Outperform |
| Apr-01-25 | Initiated | Jefferies | Buy |
| Nov-29-23 | Resumed | BTIG Research | Buy |
| Aug-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-31-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-31-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-22 | Downgrade | Needham | Buy → Hold |
| Mar-31-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-19 | Reiterated | Needham | Buy |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-11-19 | Reiterated | H.C. Wainwright | Buy |
| May-02-19 | Initiated | JP Morgan | Overweight |
| Mar-20-19 | Initiated | Citigroup | Neutral |
| Sep-07-18 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-18 | Reiterated | Needham | Buy |
| Jun-06-18 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-17 | Initiated | Piper Jaffray | Overweight |
| Dec-07-17 | Initiated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-10-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | Needham | Buy |
| Dec-27-16 | Reiterated | H.C. Wainwright | Buy |
| Dec-20-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-15-16 | Initiated | Aegis Capital | Buy |
| Sep-29-16 | Initiated | Brean Capital | Buy |
| Mar-16-16 | Reiterated | Needham | Buy |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
View All
Akebia Therapeutics Inc Stock (AKBA) Latest News
Weiss Ratings Reiterates Sell (D-) Rating for Akebia Therapeutics (NASDAQ:AKBA) - MarketBeat
Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Akebia Therapeutics Achieves Multibagger Status with 123.31% Stock Increase Over Past Year - Markets Mojo
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Profit Outlook - simplywall.st
What drives Akebia Therapeutics Inc stock priceInsider Buying Signals & Free Daily Market Summary and Trend Reports - earlytimes.in
Can Akebia Therapeutics Inc. (AX9) stock resist broad market declines2025 Major Catalysts & AI Powered Buy/Sell Recommendations - newser.com
How Akebia Therapeutics Inc. stock performs in interest rate cyclesProduct Launch & Daily Entry Point Alerts - newser.com
What to expect from Akebia Therapeutics Inc. in the next 30 days2025 Year in Review & Real-Time Stock Price Movement Reports - newser.com
How Akebia Therapeutics Inc. stock reacts to inflationary pressuresMarket Weekly Review & Low Drawdown Trading Techniques - newser.com
Should I hold or sell Akebia Therapeutics Inc. stock in 2025Trade Volume Summary & Advanced Technical Analysis Signals - newser.com
Published on: 2025-10-03 06:28:34 - newser.com
Is Akebia Therapeutics Inc. stock poised for growthRate Hike & Weekly High Conviction Ideas - newser.com
Will Akebia Therapeutics Inc. (AX9) stock profit from AI boom2025 Major Catalysts & Free Growth Oriented Trading Recommendations - newser.com
Leading vs lagging indicators on Akebia Therapeutics Inc. performanceJuly 2025 Sector Moves & Reliable Breakout Forecasts - newser.com
Why Akebia Therapeutics Inc. (AX9) stock is a strong buy callEarnings Recap Summary & Precise Trade Entry Recommendations - newser.com
Is Akebia Therapeutics Inc. stock entering bullish territoryJuly 2025 Technicals & Community Trade Idea Sharing Platform - newser.com
Is Akebia Therapeutics Inc. (AX9) stock attractive for dividend growthWeekly Trend Report & AI Based Trade Execution Alerts - newser.com
Why ETFs are accumulating Akebia Therapeutics Inc. (AX9) stockProfit Target & Fast Exit/Entry Strategy Plans - newser.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
204,163 Stock Options: Akebia Therapeutics Awards New Employee Grants with 4-Year Vesting Terms - Stock Titan
Published on: 2025-10-01 08:27:07 - newser.com
Why Akebia Therapeutics Inc. is moving todayTreasury Yields & High Accuracy Trade Signal Alerts - newser.com
How Akebia Therapeutics Inc. (AX9) stock moves in volatile trading sessions2025 Breakouts & Breakdowns & Safe Investment Capital Preservation Plans - newser.com
Published on: 2025-09-30 03:08:07 - newser.com
Atul Ltd (ATUL)’s Trend in 2025Head and Shoulders Patterns & Free Daily Investment Newsletter Subscription - earlytimes.in
Published on: 2025-09-28 22:31:40 - newser.com
Will Analyst Upgrades Continue to Fuel Sumeru Industries Limiteds RallyStock Buyback Updates & Free Triple Digit Wealth Increase - Early Times
Akebia Therapeutics Inc Stock (AKBA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.54%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):